NEW YORK – For breast cancer patients with ductal carcinoma in situ, clinicians generally have used tumor size and grade to determine treatment options, but PreludeDx has worked to provide a more precise and comprehensive option for these patients.
Radiomics firm PreludeDx's DCISionRT test can determine the benefits of radiation therapy in patients with DCIS and is intended to help radiology oncologists and surgeons pinpoint the best course of action for a patient and better personalize treatment.